Aspire BioPharma is trading 6.03% up now at $7.70, with the move appearing primarily linked to stronger biotech sentiment.
- The sector ETF is up 2.09% during regular trading.
- No fresh company-specific announcement was identified for August 6, 2026.
- Sector optimism has been supported by Argenx’s tender offer to acquire Forte Biosciences, renewing biotechnology merger-and-acquisition speculation; recent sharp volatility also suggests active speculative trading.